Clinical Trial

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-22; most recent amendment 2025-12-29.
Trial Details
NCT Number NCT07093814
Lead Sponsor Guangzhou Virotech Pharmaceutical Co., Ltd.
Conditions Glioblastoma
Enrollment 42 participants
Start Date 2025-09-02
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-02